SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) entered into a Binding Letter of Intent to complete a StemSource® Cell Bank sales agreement with Astrea International. Astrea has committed to purchase one StemSource Cell Bank for Singapore following receipt of regulatory clearance in Singapore on a pending application on the use of the Celution® System for tissue banking. In addition, Astrea has obtained rights from Cytori to commercialize additional StemSource Cell Banks in Malaysia and Brunei.
